Cas No.: | 319460-94-1 |
Chemical Name: | N-[2-fluoro-5-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]amino]phenyl]-2,5-dimethylpyrazole-3-carboxamide |
Synonyms: | AG 13958,AG-13958 |
SMILES: | C1C=NC(=CC=1)/C=C/C2C3=C(NN=2)C=C(C=C3)NC4=CC(=C(F)C=C4)NC(=O)C5N(C)N=C(C)C=5 |
Formula: | C26H22FN7O |
M.Wt: | 467.497 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | AG13958 is a VEGF inhibitor that was clinical development by Pfizer in 2006-07 for treatment of age-related macular degeneration (AMD). The drug displays low water solubility and so far in trials delivery has been difficult needing direct injection to be truly effective and it varied by the species used because of species specific differences in eye circulation and vascularization. As a VEGF inhibitor AG13958 was targeted to FLT/TYK receptor inhibition. |